Biogen prices new ALS drug at more than $14K per dose
Biogen has priced its new ALS drug Qalsody at $14,230 per dose, a spokesperson confirmed to Endpoints News on Monday.
Qalsody, also known as tofersen, won an accelerated approval last week for a rare type of ALS marked by a mutation called SOD1. Only about 1% or 2% of ALS patients have the mutation, representing about 300 people in the US, according to Biogen.
At 14 doses the first year and 13 doses each year after, Qalsody amounts to more than $199,200 the first year and nearly $185,000 in subsequent years, a spokesperson confirmed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
